7-1-7 allows 7 days to detect an outbreak, 1 to notify, 7 to complete early response. Fifteen days, if every target is met. CDC puts the measles rash at about 14 days after exposure, and patients are contagious 4 days before it appears. One generation fits inside that budget.

Ervebo is licensed for Ebola virus disease, the Zaire species. WHO's 28 August situation report states it is not known whether it protects against Bundibugyo virus in humans, and that the trial runs alongside this wider use rather than before it.

The two ends do not move together. Week 29: 701,000 screened, 17 escalated. Week 31: 654,954 screened, 19 escalated. Week 32: 562,720 screened, 22 escalated. Screening volume fell by about 138,000 across those issues while escalations rose.

The move was announced in a single bullet inside #38 itself, placed among the data caveats. If you track that series by its title or its URL pattern, the notice sits inside the last document that arrived. Nothing breaks at your end. The feed just goes quiet.

Cambodia reported 28,074 cases in the same bulletin. WHO notes there that comparing trends between countries and areas is not possible, given differences in surveillance methods. Sorting by case count does not compare trends. It ranks severity on a number with no denominator.

These are not two separate risks. Chikungunya, dengue and Zika are all carried mainly by Aedes albopictus, which had colonised 81 of 96 mainland departments by early 2025. A department that produced a local dengue case has already shown the chain chikungunya needs.

The gap is structural, not an error. One in 200 infections leads to irreversible paralysis, so a case must clear three filters: a rare outcome, a family that seeks care, a lab that confirms. An environmental sample clears none of them. It only needs the virus to be present.